Market capitalization | $1.03b |
P/B ratio (TTM) P/B ratio | negative |
Cash position | $220.66m |
P/E forward | negative |
P/S forward | 477.83 |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
4 Analysts have issued a Upstream Bio forecast:
4 Analysts have issued a Upstream Bio forecast:
Sep '24 |
+/-
%
|
||
Revenue | 0.61 0.61 |
-
|
|
Gross Profit | 0.59 0.59 |
-
|
|
EBITDA | -19 -19 |
-
|
EBIT (Operating Income) EBIT | -19 -19 |
-
|
Net Profit | -16 -16 |
-
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Upstream Bio, Inc. is a clinical-stage biotechnology company, which engages in the development of treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It develops verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin. The company was founded in April 2021 and is headquartered in Waltham, MA.
Head office | United States |
CEO | E. Sutherland |
Employees | 35 |
Website | www.upstreambio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.